Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Bioverativ

Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Bioverativ (NASDAQ: BIVV) has expired.

As quoted in the press release:

On February 7, 2018, Sanofi commenced a tender offer (the “Offer”) to purchase all outstanding shares of common stock of Bioverativ (the “Shares”) for $105 per share in cash, without interest thereon and net of any required tax withholding. As a result of the expiration of the waiting period under the HSR Act, the condition to the Offer relating to antitrust approvals has been satisfied.
The consummation of the Offer remains subject to various conditions, including the tender of at least a majority of the Shares outstanding immediately prior to the expiration of the Offer, redelivery of a tax opinion delivered at signing, and other customary conditions described in the Offer to Purchase filed by Sanofi with the U.S. Securities and Exchange Commission (the “SEC”) on February 7, 2018.

Click here to read the full press release.